ALX Oncology Holdings Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Okay. All right. Good morning, and welcome to our fireside chat with ALX Oncology. I'm Li Watsek, a biotech analyst here at Cantor and very pleased to be joined today by CEO, Jason Lettmann; and CSO, Jaume Pons. Thank you both for being here today.
Jason, nice to meet you in person and congrats on the new role as the CEO. So maybe to level set for our audience, give us a high-level overview, talk about what's coming up and maybe touch on your decision to join ALX now ahead of some pretty big data readout.
Great. Well, thanks for having us. Appreciate the Cantor team allowing us to talk to you about ALX. We're excited about where we sit. I've joined about three weeks ago, so please direct all the difficult questions to Jaume. But for me, I've been involved in ALX since the earliest days. So helped launch the company back in 2014 out of Stanford and have been on the Board there. So although I'm new very much close to the story and the company over many years.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |